

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Canceled)
2. (Currently Amended) An isolated nucleic acid molecule comprising a ~~polynucleotide having SEQ ID NO: 47 or a functional variant thereof having at least 95% identity to SEQ ID NO: 47~~, wherein said nucleic acid molecule ~~polynucleotide and functional variant thereof confer~~ confers vascular-preferred polynucleotide transcription.
3. (Canceled)
4. (Currently Amended) An isolated nucleic acid molecule ~~polynucleotide~~ having a sequence selected from
  - (a) a sequences complementary to any of the sequences in SEQ ID NO: 47 claim 2;  
and
  - (b) a sequences that are is a reverse complements to any of the sequences in SEQ ID NO: 47 claim 2;wherein said sequence is at least 30 nucleotides in length and confers vascular-preferred polynucleotide transcription.
5. (Previously Presented) The isolated nucleic molecule of claim 2, wherein said polynucleotide confers xylem-preferred gene expression in a plant cell.
6. (Previously Presented) The isolated nucleic molecule of claim 2, wherein said polynucleotide is capable of upregulating or downregulating the expression of an operably-linked gene in a plant cell.
- 7-20. (Canceled)